Post Surgical Infection Articles & Analysis
3 news found
Destiny Pharma attended the discussion and was very pleased that the meeting reinforced the Company’s conviction in infection prevention as a key component in the management of serious hospital-acquired infections. ...
The aim of the announced Phase 3 clinical programme is to deliver comprehensive clinical trial data demonstrating that nasal decolonisation using XF-73 Nasal, alongside “standard of care”, reduces the incidence of post-surgical infections in patients. This meets the requirements of both the US and EU regulators – the FDA and ...
Neil Clark, CEO of Destiny Pharma, said: “We are very pleased with the continuing progress of our novel XF-73 Dermal infection programme which is targeted at meeting a clear clinical need driven by the increasing incidence of diabetes across the world. There are 29 million people diagnosed in the United States alone who are at risk of developing diabetic foot ulcer ...